Episode 302: 301. Development and Validation of the American Heart Association's PREVENT Equations
At change in c stats of 0.007 or 0.0009 is not a meaningful change so I cant say we should use this over the PCE—yes this new calculator has the benefit of removal of race, and the use race-based algo...
12 Kesä 202411min
Episode 301: 300. A New Trial On Beta Blockers and COPD
The problems with observation data is real— randomized trial, U.K. researchers identified 519 patients (mean age, 68) with mostly moderate COPD (mean forced expiratory volume in 1 second [FEV1], 50%)...
11 Kesä 20246min
Episode 300: 299. When Do You Use a Cluster RCT?
When you want to do an RCT but you realize there might be some cross contamination so instead of randomizing individuals you randomize cluters or groups Lets say you want to do fluids--- what is bette...
7 Kesä 202414min
Episode 299: 298. Do We Have a Reversal Drug for DOACs? ANNEXA or Andexanet
1° outcome: hemostatic efficacy = which was defined as;(A) Hematoma expansion ≤ 35% at 12h(B) increase in NIHSS ≤ 7 at 12h(C) No rescue therapy 3-12h Results hemostatic efficacy: 76.7% andexanet vs...
6 Kesä 20249min
Episode 298: 297. Which one of the CHADVASC is worse?
In patients with atrial fibrillation (AF), how do CHA2DS2-VASc 1 subgroups compare with one another 64 141 patients with a first AF diagnosis Patients were categorized as CHA2DS2-VASc 1 if they ha...
5 Kesä 20244min
Episode 297: FIXED! 296. Is There a Drug That Will Keep Alcoholics Out of the Hospital?
Bottom line Do I think if you stop drinking alcohol in the next thirty days you are less likely to come to the hospital for a heart attack? A stroke? Pneumonia? copd exacerbations or CHF exacerbations...
30 Touko 202418min
Episode 296: 295. What is the Best Blood Pressure In the Nursing Home?
In a retrospective cohort study of Veterans Affairs (VA) nursing home residents during 2006 to 2019, researchers identified 13,000 residents who initiated a first or additional antihypertensive medica...
29 Touko 20247min
Episode 295: 294. SGLT2 Inhibitors and Stage 5 CKD
SGLT-2 inhibitors have not been evaluated in patients with stage 5 CKD (CKD 5; eGFR, ≤15 mL/minute/1.73 m2). Investigators in Taiwan retrospectively assessed 5 years of outcome data for nearly 48,000 ...
28 Touko 20245min
